Stryker reported second-quarter 2026 results on 30 July: net sales of $6.6 billion, up 9.4% reported and 9.0% organic. The number that matters for the trauma market sits inside the Orthopaedics segment, where U.S. trauma and extremities grew more than 12% in the quarter. Coming one quarter after a cyber incident knocked out production for roughly a month, the results read as a demand story, not just a recovery story: fracture procedure volumes are pulling the category forward.
The quarter in numbers
- Net sales of $6.589 billion, up 9.4% reported; organic net sales up 9.0% on increased unit volume.
- Orthopaedics segment sales of about $3.0 billion, up 9.1% reported and 8.6% organic.
- Adjusted EPS of $3.69, up 17.9%; reported EPS of $3.30, up 44.1%.
- Adjusted operating margin expanded 170 basis points to 27.4%.
- Full-year guidance narrowed to 8.3%–9.3% organic sales growth and $14.95–$15.10 adjusted EPS.
Management framed the quarter as a recovery from the March 2026 cybersecurity incident, which idled manufacturing for nearly a month in Q1. Investors wanted a bigger guidance raise and sent the shares down about 9% after hours, but the operating metrics — volume growth, margin expansion, record Mako installations — all moved the right way.
Trauma keeps outpacing the rest of orthopedics
The trauma and extremities line has been Stryker's strongest orthopedic business for a while. It grew 12.6% to $3.94 billion for full-year 2025, and the Q2 call put U.S. trauma and extremities growth above 12% again. Two forces sit behind that run. Fracture volumes rise with an aging, active population, and the category keeps absorbing product launches — the T2 Alpha nailing platform, the Pangea plating system rollout in Europe, and new syndesmotic fixation devices — that pull hospitals toward platform standardization. For the wider supply chain, double-digit growth in the leading trauma franchise is a reliable proxy for procedure demand across plates, screws and nails.
What this signals for trauma buyers
Three practical signals for hospitals and distributors. First, trauma procedure volumes are growing faster than most orthopedic categories, so implant consumption in hip and femur nailing and extremity plating will keep climbing through 2026. Second, the largest trauma supplier has only just cleared a month-long production outage, which means factory allocation across the industry stays tight and distributor-held stock keeps its buffer value. Third, platform standardization is accelerating: buyers reviewing their foot and ankle plating or nailing contracts should expect suppliers to push bundled platform pricing rather than piecemeal discounts.
The BoneCraft angle
BoneCraft is an independent distributor of genuine trauma implants. We track the big manufacturers' results because their demand cycles shape lead times and allocation across the whole market. When factory channels tighten, warehouse stock is what keeps a hospital's trauma program supplied. Contact our team for current availability across plates, nails and screws.
Sources
- Stryker Reports Second Quarter 2026 Operating Results — GlobeNewswire, 30 July 2026
- Stryker Investor Relations — Press Releases and 2026 Outlook
- Beta Finch — Stryker Q2 2026 Earnings Call Analysis: U.S. Trauma and Extremities Growth Over 12%
- Medical Device Network — Stryker FY2025: Trauma and Extremities Up 12.6% to $3.94 Billion
Stryker, Mako, T2 Alpha and Pangea are trademarks of their respective owner. BoneCraft is an independent distributor of genuine orthopedic trauma implants and is not affiliated with, sponsored by, or endorsed by Stryker or any other manufacturer mentioned.
-
BrandName Team
Process Media Manufacturer Since 2010
pproduces tower packing, molecular sieves, ceramic grinding media and other process media from our Pingxiang production base. We supply to industrial projects in over 100 countries.
